Her2 In Breast Cancer - Genetic Mutations

Relevant Publications

[Pharmacological properties and clinical development overview of pertuzumab (genetical recombination), trastuzumab (genetical recombination) and vorhyaluronidase alfa (genetical recombination) (PHESGO combination for ‍subcutaneous injection MA, IN)].

Issue Release: 2024

mTORC1-driven protein translation correlates with clinical benefit of capivasertib within a genetically preselected cohort of PIK3CA-altered tumours.

Issue Release: 2024

Effect of cross-platform gene-expression, computational methods on breast cancer subtyping in PALOMA-2 and PALLET studies.

Issue Release: 2024

A prospective study of HER3 expression pre and post neoadjuvant therapy of different breast cancer subtypes: implications for HER3 imaging therapy guidance.

Issue Release: 2024

Surgical outcomes and prognosis of HER2+ invasive breast cancer patients with a DCIS component treated with breast-conserving surgery after neoadjuvant systemic therapy.

Issue Release: 2024

Lasofoxifene as a potential treatment for aromatase inhibitor-resistant ER-positive breast cancer.

Issue Release: 2024

Human-derived Tumor-On-Chip model to study the heterogeneity of breast cancer tissue.

Issue Release: 2024

Electroporation enhances cell death in 3D scaffold-based MDA-MB-231 cells treated with metformin.

Issue Release: 2024

Biological activity of a stable 6-aryl-2-benzoyl-pyridine colchicine-binding site inhibitor, 60c, in metastatic, triple-negative breast cancer.

Issue Release: 2024

Immunohistochemical Profile of Triple-Negative Breast Cancers: SOX10 and AR Dual Negative Tumors Have Worse Outcomes.

Issue Release: 2024

Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B.

Issue Release: 2024

Biomarker conversion from primary breast cancer to synchronous axillary lymph node metastasis and neoadjuvant therapy response: a single-center analysis.

Issue Release: 2024

Ferroptosis as a promising targeted therapy for triple negative breast cancer.

Issue Release: 2024

Impact of coadministration of proton-pump inhibitors and palbociclib in hormone receptor-positive/HER2-negative advanced breast cancer.

Issue Release: 2024

Real-world Outcomes of Dual HER2 Blockade Therapy in Metastatic HER2-Positive Breast Cancer: from Induction to Maintenance.

Issue Release: 2024

The G Protein Estrogen Receptor (GPER) is involved in the resistance to the CDK4/6 inhibitor palbociclib in breast cancer.

Issue Release: 2024

Cubosomes functionalized with antibodies as a potential strategy for the treatment of HER2-positive breast cancer.

Issue Release: 2024

Dual inhibition of the TrkA and JAK2 pathways using entrectinib and pacritinib suppresses the growth and metastasis of HER2-positive and triple-negative breast cancers.

Issue Release: 2024

Correction to: HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging.

Issue Release: 2024

Male breast cancer: a multicenter study to provide a guide for proper management.

Issue Release: 2024

What Are Developmental Disorders?

Are All Nucleotide Mutations Harmful?

What is a Nucleotide?

What are the Chances of Inheriting an Autosomal Recessive Disorder?

Why are TKIs Effective Against Certain Cancers?

How do Environmental Factors Influence Genetic Mutations?

What Is the Significance of Synonymous Mutations in Evolution?

What Are Some Examples of Genetic Disorders Caused by Mutations?

How Can Hemophilia Be Managed?

What is Genetic Coding?

Her2 In Breast Cancer - Genetic Mutations

Relevant Publications

Partnered Content Networks

Relevant Topics